Thinly traded micro cap Aquestive Therapeutics (AQST +18.2%) is up on more than a 7x surge in volume, albeit on turnover of only 790K shares, in reaction to its Q3 report that included a guidance raise. Highlights:
Revenues: $12.4M (-6.8%).
Net loss: ($18.4M) (-22.6%); loss/share: ($0.74) (-15.6%).
Non-GAAP EBITDA: ($8.4M) (-16.7%).
Rolling NDA for Libervant Buccal Film should be completed this quarter.
2019 guidance: Revenues: $45M - 47M from $38M - 45M; non-GAAP EBITDA loss: ($50M - 49M) from ($52M - 50M).
Previously: Aquestive Therapeutics EPS misses by $0.04, beats on revenue (Nov. 5)
Try Seeking Alpha PREMIUM for unlimited analysis on AQST